ClinicalTrials.gg
Not yet recruitingNCT07035444Updated Jun 25, 2025

Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer

An interventional study of L-Carnitine 4g and Enteral Nutrition in Non-Small Cell Lung Cancer and Cachexia, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Carcinoma, Non-Small-Cell Lung by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University — 6 open to participants now, 6 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

Planned enrollment
7th of 11
126 · median 150
Started
2025
with 1 other
No phase
3 of 16
3 open now
Registered
14th of 16
by date

Among the 16 studies in Carcinoma, Non-Small-Cell Lung by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 with no phase, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 16 studies in Carcinoma, Non-Small-Cell Lung by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Carcinoma, Non-Small-Cell Lung by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, or all of them as a file.
02

Study summary

This is a multicenter, double-blind randomized controlled clinical study designed to evaluate the efficacy and safety of oral nutritional supplements (ONS) containing levocarnitine for cachexia in lung cancer patients scheduled for or undergoing chemotherapy.

Study Design:

Recruitment: Approximately 126 pathologically confirmed patients meeting the inclusion criteria will be enrolled across four hospitals (Army Characteristic Medical Center, Chongqing Fifth People's Hospital, Chongqing Thirteenth People's Hospital, and Chongqing Qianjiang District Central Hospital). The planned enrollment is 60 patients at Army Characteristic Medical Center, 22 at Chongqing Fifth People's Hospital, 22 at Chongqing Thirteenth People's Hospital, and 22 at Chongqing Qianjiang District Central Hospital.

Randomization: Patients will be randomly assigned in a 1:1 ratio to the control group (63 patients) or the intervention group (63 patients).

Interventions:

Control Group: Receive 500 mL of enteral nutrition solution daily for 12 weeks (84 days).

Intervention Group: Receive 500 mL of enteral nutrition solution containing 4 g of levocarnitine daily for 12 weeks (84 days).

Evaluations:

Efficacy Assessments: Body composition analysis and other evaluations will be conducted at baseline and after ONS treatment with levocarnitine to assess the effectiveness of the intervention.

Safety Assessments: Safety events during the levocarnitine-containing ONS treatment period and within 28 days after neoadjuvant therapy will be collected to evaluate treatment safety.

Follow-up: After chemotherapy, the investigator will determine the optimal adjuvant treatment and follow-up protocols to assess recurrence and survival outcomes.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Cachexia

Keywords

  • L-carnitine
  • Enteral nutrition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Primary lung tumor confirmed by cytology or histology; 2.Meeting the diagnostic criteria for cachexia (with one of the following criteria):

    1. Weight loss >5% in the past 6 months (without active weight loss);
    2. (BMI) \<20 and weight loss >2%;
    3. Decreased total skeletal muscle index (detected by bioelectrical impedance analysis: \<7.26 kg/m² for males; \<5.45 kg/m² for females) and weight loss >2%; 3.Age ≥18 years; 4.Patients scheduled to receive or currently undergoing chemotherapy; 5.Patients with an expected survival period ≥3 months; 6.Signed written and able to comply with the study visit schedule and relevant procedures; 7.Sufficient organ function before the first study treatment (no use of any blood components, leukocyte-elevating drugs, or -elevating drugs within 14 days prior to randomization):

    <!-- -->

    1. ≥1.5×10⁹/L;
    2. Platelet count ≥100×10⁹/L;
    3. >90 g/L;
    4. Serum creatinine \<1.5× (ULN) or (CLcr) calculated by the Cockcroft-Gault formula >50 mL/min;
    5. Total \<1.5×ULN (for Gilbert syndrome patients, \<3×ULN is acceptable);
    6. and ALT \<2.5×ULN (for patients with liver , ≤5×ULN);
    7. (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN, unless the subject is receiving anticoagulant therapy

Exclusion criteria

Exclusion Criteria:

  • 1.Patients scheduled for lung cancer surgery within the next 3 months; 2.Patients with uncontrolled hyperglycemia after adequate treatment; 3.Patients allergic to levocarnitine; 4.Patients with to enteral nutrition, including but not limited to active gastrointestinal bleeding, complete intestinal obstruction, etc.; 5.Patients with diseases severely affecting digestion and absorption, including but not limited to subtotal gastrectomy, history of intestinal surgery, etc.; 6.Patients with cardiovascular and cerebrovascular diseases, including but not limited to:

    1. Myocardial infarction or unstable angina within 6 months before the first drug administration;
    2. Stroke or within 6 months before the first drug administration;
    3. Hypertension that cannot be controlled after optimal antihypertensive treatment (systolic blood pressure >160 mmHg and/or diastolic blood pressure ≥100 mmHg);
    4. Patients with clinically significant arrhythmia who have been stable for >14 days before the first drug administration may be enrolled;
    5. Congestive heart failure ( [NYHA] functional classification > Class 3; see Appendix VI for details);
    6. Myocarditis; 7.Patients currently participating in interventional clinical research treatment, or who have received other drugs or devices within 4 weeks prior to randomization; 8.Active tuberculosis or tuberculosis requiring medical intervention at the current stage, including but not limited to pulmonary tuberculosis; 9.Patients with known mental illnesses or substance abuse that may affect compliance with trial requirements, or a history of alcohol abuse; 10.Patients with medical history, diseases, treatments, or laboratory abnormalities that may interfere with trial results or prevent the subject from participating in the study throughout the process, or where the investigator deems participation not in the subject's best interest; 11.Local or systemic diseases caused by non-malignant tumors, or secondary reactions to cancer, which may lead to higher medical risks and/or uncertainty in survival evaluation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
126 participants (estimated)

Study arms

  • Active comparator
    Enteral nutrition

    During the entire study period (84 days), research participants will receive 500 ml of enteral nutrition solution daily. The nutrition is provided in two 55 g packets of nutritional powder. Each packet is dissolved in 220 ml of warm boiled water at 55°C to prepare 250 ml of the nutrition solution. Depending on the individual circumstances of the research participants, the solution can be taken in 2 to 3 divided doses daily, with a total daily volume of 500 ml.

    Dietary Supplement: Enteral Nutrition

  • Experimental
    Enteral Nutrition with L-Carnitine

    During the entire study period (84 days), research participants will receive 500 ml of enteral nutrition solution containing 4 g of L-carnitine daily. The nutrition consists of two 55 g packets of nutritional powder. Each packet is dissolved in 220 ml of warm boiled water at 55°C to make 250 ml of the nutrition solution. Depending on the individual situation of the research participants, the solution can be taken in two to three divided doses daily, with a total daily volume of 500 ml

    Dietary Supplement: L-Carnitine 4g

Interventions

  • Dietary supplementL-Carnitine 4g

    500ml enteral nutrition solution containing 4g of L-carnitine

  • Dietary supplementEnteral Nutrition

    Enteral nutrition was given 500 ml per day for a total of 84 days.

06

What researchers measure

Primary outcomes

  1. Total Skeletal Muscle Mass

    The total skeletal muscle mass (TSMM) is the primary endpoint of this study. It is defined as the total weight of skeletal muscles throughout the human body, typically expressed in kilograms (kg). This assessment is conducted using a body composition analyzer.

    Time frame: At enrollment, Day 21, Day 42, Day 63, Day 84, six months, and 12 months

Secondary outcomes

  1. BMI

    The body mass index (BMI) is defined as a value obtained by dividing body weight (in kilograms) by the square of height (in meters). The formula is: weight / height²

    Time frame: At enrollment, Day 21, Day 42, Day 63, Day 84, six months, and 12 months

  2. Grip strength

    It is defined as the force generated by the contraction of hand muscles. This force reflects the comprehensive strength level of hand flexor muscles (such as the flexor digitorum superficialis, flexor digitorum profundus, and flexor pollicis longus) and related muscle groups (such as the thenar muscles and hypothenar muscles). To some extent, it can reflect an individual's overall muscle strength and physical function status. This assessment is measured using an electronic grip dynamometer.

    Time frame: At enrollment, Day 21, Day 42, Day 63, Day 84, six months, and 12 months

  3. Inflammatory cytokines

    Inflammatory molecules refer to a class of bioactive substances produced and released during the inflammatory response, which play a key role in the initiation, development, and regulation of inflammation. This assessment uses interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP).

    Time frame: At enrollment, Day 21, Day 42, Day 63, Day 84, six months, and 12 months

  4. Nutritional Score

    The nutritional score is defined as a quantitative method used to assess the nutritional status of individuals or groups, and this assessment is measured using PG-SGA and NRS2002.

    Time frame: At enrollment, Day 21, Day 42, Day 63, Day 84, six months, and 12 months

  5. Quality of Life Score

    The quality of life score is a quantitative evaluation of the quality of life of individuals or groups, and this assessment is conducted using the EORTC QLQ-C30 C3.0 Chinese version (Quality of Life Questionnaire for Lung Cancer Patients).

    Time frame: At enrollment, Day 21, Day 42, Day 63, Day 84, six months, and 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Jun 2026, 12 months later.

Of 344 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's planned 12 months is below that.

Counting every sponsor, half of 360 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 25, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07035444
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 25, 2025

Study contacts

shiqiao CHEN
Contact
csq-ly@tmmu.edu.cn
86+ 15340490583
Hongxia xu
Contact
hongxia Xu
study director · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carnitine

Start the discussion